Cancell
Cancell is a liquid substance that has been marketed as a potential treatment for various types of cancer, although it has not received approval from the FDA. Its development dates back to the late 1930s by biochemist James V. Sheridan, who theorized that Cancell could alter cancer cells by affecting their respiration, potentially allowing the immune system to recognize and eliminate them. The product has been manufactured since 1984 by Edward J. Sopcak, who proposed that Cancell might disrupt the vibrational frequency of cancer cells, rendering them more vulnerable to the body’s defenses.
Despite these claims, laboratory studies conducted by the National Cancer Institute revealed that Cancell could not be safely administered at effective doses for killing cancer cells, leading to the conclusion that it lacked sufficient anticancer activity. Additionally, no peer-reviewed clinical trial data supports its efficacy. Some peer-reviewed literature has emerged, but concerns about potential conflicts of interest are present, as some authors were linked to manufacturers of similar products. Side effects of Cancell reportedly include fatigue, nausea, and diarrhea, and there is a risk of disease progression if conventional treatment is neglected while using it. As such, it is critical for individuals considering Cancell to consult healthcare professionals and rely on established cancer treatments.
On this Page
Subject Terms
Cancell
Also known as:Cantron, Entelev, Jim’s Juice, JS-114, JS-101, 126-F, Protocel, Quantrol, Radic, Sheridan's Formula
Definition:Cancell (previously known as Entelev) is a controversial and unapproved therapy developed in the late 1930s. Cancell is a combination of chemicals that is thought to kill cancer cells by affecting their cellular respiration and/or electrical voltage. Studies conducted in the late 1970s through early 1990s found that Cancell's effects were too negligible to be effective against cancer, and in 1989, the US Food and Drug Administration (FDA) declared it illegal for manufacturers to sell and/or transport Cancell across state lines.
Cancers treated or prevented: The manufacturers claim that Cancell can treat all types of cancer; however, it is not approved by the FDA.
Delivery routes: Cancell is in liquid form and has been taken by mouth, inserted into the rectum, or applied to the skin (on the wrist or ball of the foot).
How this substance works: Cancell (then known as Entelev) was first envisioned in the late 1930s by the biochemist James V. Sheridan. In 1984, Edward J. Sopcak began making Cancell. Sheridan believed that Cancell affects cellular respiration, a chemical process that uses oxygen and provides energy to a cell. He further speculated that cells that do not require oxygen for respiration are “primitive” and that these primitive cells may be recognized, attacked, and killed by the body’s immune system or through other processes. Accordingly, Sheridan believed that Cancell could change cancer cells to a primitive state. Similarly, Sopcak thought that Cancell affected the vibrational frequency and energy of cancer cells, which may disrupt cancer proteins and change cancer cells to primitive cells. In either theory, the hypothesis is that Cancell makes cancer cells become primitive, which would allow the body to get rid of them.
Cancell contains various ingredients, including the chemicals inositol, nitric acid, sodium sulfite, potassium hydroxide, sulfuric acid, and catechol. Laboratory studies conducted by the National Cancer Institute (NCI) between the late 1970s and early 1990s found that Cancell could not be taken safely by humans at doses high enough to kill cancer cells. Therefore, the NCI concluded that Cancell did not show sufficient anticancer activity to merit continuing the studies. Furthermore, no studies of Cancell (in either animals or humans) or clinical trial data were published in peer-reviewed scientific journals.
In 2013 the first peer-reviewed article on the possible anticancer properties of Cancell was published in Current Topics in Nutraceutical Research. Study authors Fred Valeriote, Joseph Media, Matthew Edelstein, and Russell Betts found that Cantron (a dietary supplement formulation on Cancell still on the market) exhibited selectivity for human murine colon cancer cells and that the catechol in Cantron is toxic to many different cancers; however, all four disclosed that they were shareholders in and received funding from a supplement manufacturer, which subsequently produced its own brand of Cancell called Cantavita.
Side effects: The main side effects of Cancell (and look-alike dietary supplements) include tiredness during the first few weeks of treatment, as well as nausea and diarrhea. There may also be disease progression if the affected individual does not follow conventional treatment while using it.
Bibliography
"Cancell." Cancer.org. Amer. Cancer Soc., 7 June 2013. Web. 18 Sept. 2014.
"Cancell/Cantron/Protocel." Cancer.gov. Natl. Cancer Inst., Natl. Inst. of Health, 3 Feb. 2014. Web. 18 Sept. 2014.
Cassileth, Barrie R., K. Simon Yeung, and Jyothirmai Gubili. Herb-Drug Interactions in Oncology. Shelton: Memorial Sloan-Kettering Cancer Center, Integrative Medicine Science, 2010. Print.
Segal, Marian. "Court Says to Cancel the Cancell." FDA Consumer 27.4 (1993): 40. Print.
Valeriote, Fred, et al. "In Vitro Anticancer Studies on Cantron and Its Constituents." Current Topics in Nutraceutical Research 11.1–2 (2013): 9–14. PDF file.